import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "how-to-use-bpc-157-research-protocol-guide",
  title: "How to Use BPC-157: Research Protocol Guide (2026)",
  description:
    "A practical research protocol reference for BPC-157 — covering reconstitution, administration routes, dosing windows, and study design considerations based on preclinical literature.",
  category: "Research Protocols",
  readMinutes: 10,
  publishedAt: "2026-06-20",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "BPC-157 is one of the most extensively studied synthetic peptides in preclinical literature, with research spanning gastrointestinal protection, musculoskeletal repair, neuroprotection, and systemic anti-inflammatory effects. For researchers setting up a BPC-157 protocol, the practical steps — reconstitution, route selection, dosing windows, and endpoint tracking — matter as much as the underlying biology.",
    },
    {
      type: "callout",
      text: "This guide is for research purposes only. BPC-157 is a research compound and is not approved for human use by the FDA or any equivalent regulatory body.",
    },
    {
      type: "heading",
      text: "Step 1: Verify Your Source Material",
    },
    {
      type: "paragraph",
      text: "Before beginning any protocol, verify the COA (Certificate of Analysis) for your BPC-157 material. Research-grade BPC-157 should meet the following minimum standards:",
    },
    {
      type: "list",
      items: [
        "HPLC purity ≥99% — confirms the primary compound percentage",
        "Mass spectrometry (MS) confirmation — verifies molecular identity (MW ~1,420 Da)",
        "LAL endotoxin testing — confirms absence of bacterial lipopolysaccharides",
        "Lyophilized form — stable for storage and shipping",
        "Third-party or independent lab testing — not solely supplier-generated",
      ],
    },
    {
      type: "paragraph",
      text: "Impure or degraded BPC-157 will produce unreliable results and may introduce confounding variables into experimental outcomes.",
    },
    {
      type: "heading",
      text: "Step 2: Reconstitution",
    },
    {
      type: "paragraph",
      text: "Lyophilized BPC-157 must be reconstituted before use. The standard diluent in research settings is bacteriostatic water (0.9% benzyl alcohol in sterile water for injection) or sterile 0.9% saline. Bacteriostatic water is preferred for multi-use vials due to its antimicrobial properties.",
    },
    {
      type: "subheading",
      text: "Reconstitution Protocol",
    },
    {
      type: "list",
      items: [
        "Use a sterile insulin syringe (29–31 gauge) to draw the diluent",
        "Inject diluent slowly along the inside wall of the vial — do not inject directly onto the lyophilized powder",
        "Gently swirl (do not shake) until the powder fully dissolves",
        "Resulting solution should be clear and colorless — discard if cloudy or particulate matter is visible",
        "Label vial with reconstitution date and concentration",
      ],
    },
    {
      type: "paragraph",
      text: "Common reconstitution target: 1 mg of BPC-157 in 2 mL of bacteriostatic water yields a concentration of 500 mcg/mL (0.5 mg/mL). Adjust volume based on desired working concentration.",
    },
    {
      type: "heading",
      text: "Step 3: Route of Administration",
    },
    {
      type: "paragraph",
      text: "BPC-157 has been studied via multiple routes in animal models. Route selection in research should match the experimental objective:",
    },
    {
      type: "table",
      headers: ["Route", "Notes", "Use Case in Research"],
      rows: [
        ["Subcutaneous (SC)", "Standard injection beneath skin; most common in rodent studies", "Systemic effects, injury models, general research"],
        ["Intraperitoneal (IP)", "Abdominal cavity injection; fast systemic uptake", "Systemic studies in rodent models"],
        ["Intragastric (IG) / Oral", "Gavage or dissolved in drinking water", "GI protection, gastric ulcer models"],
        ["Intramuscular (IM)", "Injection into target muscle tissue", "Local musculoskeletal repair studies"],
        ["Topical", "Experimental; limited published data", "Skin wound models"],
      ],
    },
    {
      type: "paragraph",
      text: "For most preclinical injury models in published literature, subcutaneous administration in the range of 10–100 µg/kg is most commonly used. Intragastric routes have been extensively studied for GI protection protocols.",
    },
    {
      type: "heading",
      text: "Step 4: Dosing Ranges From Published Research",
    },
    {
      type: "callout",
      text: "The following reflects dosing parameters from preclinical animal studies only. These are not clinical recommendations or human dosing guidelines.",
    },
    {
      type: "paragraph",
      text: "Preclinical BPC-157 dosing varies considerably based on model, route, and endpoint. The following ranges reflect what appears most frequently in indexed literature:",
    },
    {
      type: "list",
      items: [
        "10 µg/kg SC/IP — lower dose range; used in some systemic and GI studies",
        "50 µg/kg SC/IP — mid-range; frequently used in musculoskeletal repair models",
        "100 µg/kg SC/IP — higher dose range; used in some neurological and injury models",
        "10 µg/kg intragastric — standard dose for gastric ulcer and GI protection protocols",
        "2–10 µg/kg — some systemic and behavioral studies use these sub-10 ranges",
      ],
    },
    {
      type: "paragraph",
      text: "Duration in published studies typically ranges from 7 to 14 days post-injury, with daily or twice-daily administration being most common. Some longer studies (30+ days) have examined chronic administration in non-injury models.",
    },
    {
      type: "heading",
      text: "Step 5: Timing and Frequency",
    },
    {
      type: "paragraph",
      text: "Administration timing in research studies is typically standardized relative to injury induction. In post-injury protocols, BPC-157 is usually administered beginning 30 minutes to 24 hours after injury, then continuing once or twice daily. In prophylactic models, administration may begin days before the experimental insult.",
    },
    {
      type: "paragraph",
      text: "The short half-life of BPC-157 in solution (estimated at under 1 hour in plasma) suggests that consistent daily dosing maintains more stable tissue exposure than infrequent larger doses, though controlled pharmacokinetic studies in rodents are limited.",
    },
    {
      type: "heading",
      text: "Step 6: Storage of Reconstituted Material",
    },
    {
      type: "list",
      items: [
        "Lyophilized (unreconstituted): store at -20°C for long-term; -80°C for extended stability",
        "Reconstituted with bacteriostatic water: store at 4°C (refrigerator); use within 28–30 days",
        "Reconstituted with sterile saline: store at 4°C; use within 7 days",
        "Avoid repeated freeze-thaw cycles after reconstitution — degrades peptide bonds",
        "Protect from light; store in amber vials or foil-covered vials when possible",
      ],
    },
    {
      type: "heading",
      text: "Step 7: Endpoint Tracking and Data Collection",
    },
    {
      type: "paragraph",
      text: "Research endpoints for BPC-157 studies vary by application area. Standard tracking categories include:",
    },
    {
      type: "subheading",
      text: "Musculoskeletal Models",
    },
    {
      type: "list",
      items: [
        "Histological analysis of tendon/ligament tissue at study termination",
        "Biomechanical tensile strength testing",
        "Functional scoring (e.g., grip strength, motor function tests)",
        "Inflammatory markers: IL-6, TNF-α, CRP",
        "Angiogenesis markers: VEGF, CD31 immunostaining",
      ],
    },
    {
      type: "subheading",
      text: "GI Models",
    },
    {
      type: "list",
      items: [
        "Macroscopic ulcer scoring (ulcer index, lesion area)",
        "Histological mucosal integrity assessment",
        "Tight junction protein expression (occludin, ZO-1, claudin)",
        "Mucosal eNOS expression",
        "Body weight and food intake tracking",
      ],
    },
    {
      type: "subheading",
      text: "Neurological Models",
    },
    {
      type: "list",
      items: [
        "Behavioral assays: Morris water maze, rotarod, open field",
        "BDNF, GDNF expression (Western blot, IHC)",
        "Inflammatory cytokine panels",
        "Histological brain/spinal cord sectioning",
      ],
    },
    {
      type: "heading",
      text: "Common Research Errors to Avoid",
    },
    {
      type: "list",
      items: [
        "Using degraded peptide — always verify freshness and storage conditions before use",
        "Inconsistent injection technique — volume, site, and angle variation introduces noise",
        "Insufficient vehicle controls — BPC-157 solution vehicle (BAC water or saline) must be controlled for",
        "Single-timepoint endpoints — longitudinal tracking captures recovery dynamics more accurately",
        "Sourcing from unverified vendors — impure material invalidates results",
      ],
    },
    {
      type: "heading",
      text: "Summary",
    },
    {
      type: "paragraph",
      text: "A reliable BPC-157 research protocol requires verified starting material, careful reconstitution, route selection matched to the experimental model, consistent dosing frequency, and rigorous endpoint collection. The breadth of published preclinical data on BPC-157 provides substantial reference for protocol design across multiple research domains. For researchers new to peptide work, starting with a well-characterized single-compound study before progressing to stacking protocols is the recommended approach.",
    },
    {
      type: "callout",
      text: "For research purposes only. Not intended for human use, diagnosis, or treatment.",
    },
  ],
};
